En Carta Diagnostics Raises €5 Million

En Carta Diagnostics, a Paris-based company specializing in developing molecular tests, has successfully completed a €5 million funding round. The round was led by Blue Forest Ventures, with participation from Ring Capital, CentraleSupélec Venture, and 50 Partners Health. The company is known for creating easy-to-use molecular tests that offer the precision of PCR machines, with current offerings including early detection kits for Lyme disease and CT/NG - Chlamydia and Gonorrhea.

Funding Details

The funding round, which took place on July 11, 2026, included €3 million in equity investment. In addition to the equity, €2 million was secured through non-dilutive funding from Bpifrance and other partners. This financial boost is expected to facilitate the company's mission to enhance access to reliable diagnostic tests that can be administered at home.

Leadership and Vision

Guillaume Horréard, co-founder of En Carta Diagnostics, highlighted the company's commitment to improving patient outcomes through early diagnosis. He stated, "This first closing brings us closer to our mission of transforming access to testing. By enabling patients to perform reliable molecular tests wherever they are, we can support earlier diagnosis and help relieve pressure on healthcare systems."

Margot Karlikow, co-founder and CTO, also plays a pivotal role in driving the technological innovations behind the company's diagnostic solutions.

Use of Funds

The newly acquired funds are expected to be used to advance the development and commercial availability of En Carta's diagnostic kits. This includes expanding the range of applications for their technology, which utilizes aptamers for high-affinity and specific target binding, catering to genetic, pathogenic, and veterinary indications.

Investors

  • Lead Investor: Blue Forest Ventures
  • Other Investors: Ring Capital, CentraleSupélec Venture, 50 Partners Health

The involvement of these investors underscores the confidence in En Carta's potential to revolutionize the molecular diagnostics landscape with its innovative solutions.

With this latest funding round, En Carta Diagnostics is set to further its efforts in making advanced diagnostic testing more accessible and efficient, potentially transforming healthcare systems worldwide.